AI Plaque Mapping

The Science-Policy Narrative

The twist is reimbursement momentum. When insurers cover AI analysis, access expands rapidly—and so does scrutiny. The key question: does AI quantification reduce cardiovascular events, or does it simply increase downstream testing and interventions?

Coverage criteria are often narrow: FDA-cleared software, acute or stable chest pain with no known CAD, and qualifying CCTA findings. Plaque mapping provides more information than traditional tests, but more information isn't automatically better if it triggers procedures without improved outcomes. The luxury health service becomes a test case for AI medicine broadly.

Why It Matters for Luxury

AI heart scans illustrate how luxury health services can become standard care—and the tensions that creates. When everyone can access the premium baseline, the luxury positioning erodes. But the transition also validates the technology: insurance coverage requires evidence that payers find compelling. The question shifts from "is this exclusive?" to "is this useful?"